Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Bortezomib, carfilzomib, and ixazomib are proteasome inhibitors.
“Bortezomib, carfilzomib, and ixazomib are proteasome inhibitors.81–83”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [83]
The To the Editor section identifies bortezomib as an agent that inhibits the proteasome and explicitly calls carfilzomib a proteasome inhibitor. Our copy does not mention ixazomib, so it supports only two of the three identifications. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
Obeng, E. A., Carlson, L. M., Gutman, D. M., Harrington, W. J., Lee, K. P., & Boise, L. (2006) · Blood · doi:10.1182/blood-2005-08-3531 · Cited by 1,147 · see citing works
Self-citationKuhn, D. J., Chen, Q., Voorhees, P. M., Strader, J. S., Shenk, K. D., Sun, C. M., Demo, S. D., Bennett, M. K., van Leeuwen, F. W. B., Chanan-Khan, A. A., et al. (2007) · Blood · doi:10.1182/blood-2007-01-065888 · Cited by 776 · see citing works
Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
Demo, S. D., Kirk, C. J., Aujay, M. A., Buchholz, T. J., Dajee, M., Ho, M. N., Jiang, J., Laidig, G. J., Lewis, E. R., Parlati, F., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4086 · Cited by 681 · see citing works
The proteasome: a novel target for cancer chemotherapy
Almond, J., & Cohen, G. (2002) · Leukemia · doi:10.1038/sj.leu.2402417 · Cited by 539 · see citing works
Mechanisms of proteasome inhibitor action and resistance in cancer
McConkey, D. J., & Zhu, K. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2008.08.002 · Cited by 309 · see citing works
Friedenberg, W. R., Rué, M., Blood, E., et al. (2006) · Cancer · doi:10.1002/cncr.21666 · Cited by 146 · see citing works
Yang, H. H., Ma, M. H., Vescio, R. A., & Berenson, J. R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.001 · Cited by 88 · see citing works
Treatment of multiple myeloma: An emphasis on new developments
Kyle, R. A., & Rajkumar, S. V. (2006) · Annals of Medicine · doi:10.1080/07853890500472078 · Cited by 16 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2024) · American Journal of Hematology · doi:10.1002/ajh.27422 · Cited by 534 · see citing works
Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2011) · American Journal of Hematology · doi:10.1002/ajh.21913 · Cited by 152 · see citing works
- Authors
- Gutman, D., Morales, A. A., & Boise, L. H.
- Affiliations
- University of Miami (US)
- Corresponding author
- Boise, L H
- ORCID
- Venue
- Leukemia
- Published
- 2009-06-11
- Volume
- 23
- Issue
- 11
- Pages
- 2181-2183
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- PMC
- PMC2783738
- OpenAlex
- W2030885435
- Cited by
- 53
- References
- 8
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2022: 3 · 2021: 1 · 2020: 4 · 2019: 3 · 2018: 4 · 2017: 6 · 2016: 4 · 2015: 2 · 2014: 5 · 2013: 6 · 2012: 7
- FWCI
- 2.43
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Leukemia (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA127910)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- multidrug resistance, proteasome inhibitors, multiple myeloma, carfilzomib, nelfinavir, lopinavir, PA28α
- MeSH terms
- Bortezomib, Boronic Acids, Humans, Multiple Myeloma, Oligopeptides, Phenotype, Protease Inhibitors, Pyrazines, Drug Resistance, Multiple, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
